5月19日 - ** 诊断公司 Co-Diagnostics（CODX.O）股价上涨 78.83%，至 2.45 美元
** 该公司表示，已完成针对邦迪布吉奥病毒的PCR检测试剂开发策略，该病毒正在刚果民主共和国和乌干达引发埃博拉疫情 (link)
** 该公司表示，如有需要可迅速部署该检测，尽管其床边PCR平台仍处于监管审查阶段，尚未获批
** 此次更新紧随世界卫生组织发布的紧急声明 (link) 以及美国疾控中心针对来自受影响地区的旅客加强筛查措施 (link)
** 称快速PCR检测有助于识别病例，并改善疫情的实时追踪与防控
** 计入本次交易后，CODX今年以来累计下跌58.5%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.